跳到正文
PR Newswire 健康·· 1 小时前AI 评分41

Delonix Bioworks 与 A*STAR IDL 宣布合作推进肺炎克雷伯菌工程化 OMV 疫苗候选

Delonix Bioworks and A*STAR Infectious Diseases Labs Announce Research Collaboration to Advance Novel Engineered OMV Vaccine Candidates Against Klebsiella pneumoniae

AI 导读

Delonix Bioworks 与 A*STAR IDL 签署研究合作协议,将共同发现和开发针对肺炎克雷伯菌的工程化 OMV 疫苗候选。合作结合 Delonix 的病原细菌基因组编辑与 OMV Plus™ 平台,以及 A*STAR IDL 的转化传染病研究、临床相关细菌分离株和免疫学评估能力。肺炎克雷伯菌可致严重肺炎、血流感染和脓毒症,目前尚无获批疫苗。

正文 · 原文

, /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering next-generation outer membrane vesicle (OMV) vaccines, today announced that it has entered into a Research Collaboration Agreement with A*STAR Infectious Diseases Labs (A*STAR IDL), a research institute under Singapore's Agency for Science, Technology and Research (A*STAR).

The collaboration aims to discover and develop novel OMV-based vaccine candidates targeting Klebsiella pneumoniae (K. pneumoniae). By combining Delonix's proprietary pathogenic bacterial genome editing and OMV Plus™ platforms with A*STAR IDL's strong capabilities in translational infectious disease research, clinical relevant bacterial isolates, and immunological evaluation, the collaboration also strengthens Singapore's capabilities to translate infectious disease research towards potential interventions against antimicrobial-resistant pathogens.

K. pneumoniae is a leading cause of life-threatening pneumonia, bloodstream infections, and sepsis, posing severe risks to vulnerable patient populations. The World Health Organization (WHO) has classified carbapenem-resistant Enterobacterales, including K. pneumoniae, as critical-priority pathogens due to high levels of multi-drug resistance against standard clinical therapies [1,2,3].

Despite the significant public health burden, there are currently no licensed vaccines available for K. pneumoniae. Traditional vaccine approaches have been hindered by the pathogen's extensive genetic diversity, thick capsular polysaccharides that mask conserved surface antigens, and high antigenic variation across hypervirulent and multidrug-resistant clinical lineages. Delonix's engineered OMV approach offers a differentiated solution to overcome these barriers. By precisely editing the bacterial genome to modulate capsular interference, detoxify endotoxins, and enrich conserved native antigens on non-replicating vesicles, engineered OMVs has the potential to elicit potent innate and adaptive immune responses capable of broad cross-strain protection.

This partnership marks an important milestone in Delonix's global strategy to build collaborative networks that accelerate the translation of next-generation bacterial vaccines. Driven by a shared commitment to combating antimicrobial resistance (AMR), Delonix and A*STAR IDL will leverage their complementary strengths to generate and evaluate vaccine candidates for safety, immunogenicity, and broad cross-strain protective potential, with the aim of advancing potential preventive approaches against drug-resistant K. pneumoniae.

About Delonix Bioworks

Delonix Bioworks is a clinical-stage biotechnology company at the forefront of developing next-generation genetically engineered bacterial vaccines. Leveraging its proprietary OMV Plus™ platform, the company produces high-yield, cost-effective, and precisely engineered outer membrane vesicles (OMVs) designed for superior antigen presentation and immunogenicity. Delonix is dedicated to advancing a robust pipeline of innovative bacterial vaccine candidates addressing critical unmet needs, including vaccines targeting meningococcal group B (MenB), pertussis, gonorrhoea, and K. pneumoniae infections. Its lead candidate, DX-104, is currently in Phase I clinical trials in Australia and China.

For more information, please visit https://delonixbio.com/.

Business Development & Strategic Partnerships

Email: [email protected]

References

[1] WHO. WHO Bacterial Priority Pathogens List, 2024.

[2] WHO. Global Antibiotic Resistance Surveillance Report 2025.

[3] WHO. WHO Warns of Widespread Resistance to Common Antibiotics Worldwide. 2025.

SOURCE Delonix Bioworks

来源:PR Newswire 健康 · prnewswire.com